InvestorsHub Logo
Followers 67
Posts 16221
Boards Moderated 2
Alias Born 02/14/2011

Re: None

Thursday, 03/08/2012 4:36:08 PM

Thursday, March 08, 2012 4:36:08 PM

Post# of 110
MDVN SOARS ON JNJ NEWS 9:57 AM More on Johnson & Johnson's (JNJ +1.3%) Zytiga success: The company expects to file for FDA approval in the second half of 2012 for the prostate cancer treatment. Shares of rival Dendreon (DNDN -16.3%) react negatively to the development, while Medivation (MDVN +9.2%) soars because it's developing a prostate cancer drug that is a close version of Zytiga.